Inflammatory networks and immune surveillance of pancreatic carcinoma

Current Opinion in Immunology

Volumn 25, Issue 2, 2013, Pages 200-205

  Vonderheide, Robert H ^a   Bayne, Lauren J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD11B ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

CANCER CELL; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL KILLING; DISEASE ASSOCIATION; DISEASE COURSE; EFFECTOR CELL; HUMAN; IMMUNOSURVEILLANCE; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTIC INFILTRATION; NONHUMAN; ONCOGENE RAS; PANCREAS ADENOCARCINOMA; PATHOPHYSIOLOGY; REVIEW; STROMA; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR REJECTION;

ANIMALS; HUMANS; IMMUNOLOGIC SURVEILLANCE; INFLAMMATION; PANCREATIC NEOPLASMS;

EID: 84877052290     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2013.01.006     Document Type: Review

References (56)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
3. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol 2004, 22:329-360.
4. DuPage M., Mazumdar C., Schmidt L.M., Cheung A.F., Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012, 482:405-409.
5. Zhang B., Kracker S., Yasuda T., Casola S., Vanneman M., Homig-Holzel C., Wang Z., Derudder E., Li S., Chakraborty T., et al. Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell 2012, 148:739-751.
6. Matsushita H., Vesely M.D., Koboldt D.C., Rickert C.G., Uppaluri R., Magrini V.J., Arthur C.D., White J.M., Chen Y.S., Shea L.K., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482:400-404.
7. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Smyth M.J., Schreiber R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
8. Willimsky G., Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005, 437:141-146.
9. Yee C., Thompson J.A., Roche P., Byrd D.R., Lee P.P., Piepkorn M., Kenyon K., Davis M.M., Riddell S.R., Greenberg P.D. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med 2000, 192:1637-1644.
10. Sterman D.H., Gillespie C.T., Carroll R.G., Coughlin C.M., Lord E.M., Sun J., Haas A., Recio A., Kaiser L.R., Coukos G., et al. Interferon beta adenoviral gene therapy in a patient with ovarian cancer. Nat Clin Pract Oncol 2006, 3:633-639.
11. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
12. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
13. Mantovani A., Garlanda C., Allavena P. Molecular pathways and targets in cancer-related inflammation. Ann Med 2010, 42:161-170.
14. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012, 12:253-268.
15. Zhao F., Obermann S., von Wasielewski R., Haile L., Manns M.P., Korangy F., Greten T.F. Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology 2009, 128:141-149.
16. Clark C.E., Beatty G.L., Vonderheide R.H. Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett 2009, 279:1-7.
17. Clark C.E., Hingorani S.R., Mick R., Combs C., Tuveson D.A., Vonderheide R.H. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007, 67:9518-9527.
18. Bayne L.J., Beatty G.L., Jhala N., Clark C.E., Rhim A.D., Stanger B.Z., Vonderheide R.H. Tumor-derived granulocyte-macrophagecolony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012, 21:822-835.
19. Pylayeva-Gupta Y., Lee K.E., Hajdu C.H., Miller G., Bar-Sagi D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 2012, 21:836-847.
20. Mukherjee P., Basu G.D., Tinder T.L., Subramani D.B., Bradley J.M., Arefayene M., Skaar T., De Petris G. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 2009, 182:216-224.
21. De Monte L., Reni M., Tassi E., Clavenna D., Papa I., Recalde H., Braga M., Di Carlo V., Doglioni C., Protti M.P. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011, 208:469-478.
22. Leao I.C., Ganesan P., Armstrong T.D., Jaffee E.M. Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma. Clin Transl Sci 2008, 1:228-239.
23. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362:1605-1617.
24. Maitra A., Hruban R.H. Pancreatic cancer. Annu Rev Pathol 2008, 3:157-188.
25. Matrisian L.M., Aizenberg R., Rosenzweig A. The alarming rise of pancreatic cancer deaths in the United States: why we need to stem the tide today. Newsletter of the Pancreatic Cancer Action Network 2012.
26. Von Hoff D.D., Ramanathan R.K., Borad M.J., Laheru D.A., Smith L.S., Wood T.E., Korn R.L., Desai N., Trieu V., Iglesias J.L., et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011, 29:4548-4554.
27. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., Adenis A., Raoul J.L., Gourgou-Bourgade S., de la Fouchardiere C., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825.
28. Garbe A.I., Vermeer B., Gamrekelashvili J., von Wasielewski R., Greten F.R., Westendorf A.M., Buer J., Schmid R.M., Manns M.P., Korangy F., et al. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses. Cancer Res 2006, 66:508-516.
29. Hingorani S.R., Wang L., Multani A.S., Combs C., Deramaudt T.B., Hruban R.H., Rustgi A.K., Chang S., Tuveson D.A. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7:469-483.
30. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., Huhn R.D., Song W., Li D., Sharp L.L., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
31. Mukherjee P., Ginardi A.R., Madsen C.S., Tinder T.L., Jacobs F., Parker J., Agrawal B., Longenecker B.M., Gendler S.J. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. Glycoconj J 2001, 18:931-942.
32. + T cell immunity is impaired in pancreatic carcinoma patients. J Immunol 2008, 181:6595-6603.
33. Gabitass R.F., Annels N.E., Stocken D.D., Pandha H.A., Middleton G.W. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011, 60:1419-1430.
34. Gnjatic S., Ritter E., Buchler M.W., Giese N.A., Brors B., Frei C., Murray A., Halama N., Zornig I., Chen Y.T., et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci U S A 2010, 107:5088-5093.
35. Kraman M., Bambrough P.J., Arnold J.N., Roberts E.W., Magiera L., Jones J.O., Gopinathan A., Tuveson D.A., Fearon D.T. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2011, 330:827-830.
36. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009, 182:4499-4506.
37. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
38. Peranzoni E., Zilio S., Marigo I., Dolcetti L., Zanovello P., Mandruzzato S., Bronte V. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010, 22:238-244.
39. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004, 172:989-999.
40. Bronte V., Serafini P., De Santo C., Marigo I., Tosello V., Mazzoni A., Segal D.M., Staib C., Lowel M., Sutter G., et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 2003, 170:270-278.
41. Sinha P., Clements V.K., Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005, 174:636-645.
42. Pylayeva-Gupta Y., Grabocka E., Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011, 11:761-774.
43. Vonderheide RH, Glennie MJ: Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 2013, in press.
44. Vonderheide R.H. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007, 13:1083-1088.
45. O'Sullivan T., Saddawi-Konefka R., Vermi W., Koebel C.M., Arthur C., White J.M., Uppaluri R., Andrews D.M., Ngiow S.F., Teng M.W., et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med 2012, 209:1869-1882.
46. Rakhmilevich A.L., Buhtoiarov I.N., Malkovsky M., Sondel P.M. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors. Cancer Immunol Immunother 2008, 57:1151-1160.
47. + T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999, 162:5728-5737.
48. Sotomayor E.M., Fu Y.X., Lopez-Cepero M., Herbert L., Jimenez J.J., Albarracin C., Lopez D.M. Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor. J Immunol 1991, 147:2816-2823.
49. Melani C., Chiodoni C., Forni G., Colombo M.P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003, 102:2138-2145.
50. Bunt S.K., Sinha P., Clements V.K., Leips J., Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 2006, 176:284-290.
51. Bunt S.K., Yang L., Sinha P., Clements V.K., Leips J., Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007, 67:10019-10026.
52. + immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol 2005, 175:8200-8208.
53. Tu S., Bhagat G., Cui G., Takaishi S., Kurt-Jones E.A., Rickman B., Betz K.S., Penz-Oesterreicher M., Bjorkdahl O., Fox J.G., et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008, 14:408-419.
54. Shields J.D., Kourtis I.C., Tomei A.A., Roberts J.M., Swartz M.A. Induction of lymphoid-like stroma and immune escape by tumors that express the chemokine CCL21. Science 2010, 328:749-752.
55. Dougan M., Li D., Neuberg D., Mihm M., Googe P., Wong K.K., Dranoff G. A dual role for the immune response in a mouse model of inflammation-associated lung cancer. J Clin Invest 2011, 121:2436-2446.
56. Jaffee E.M., Hruban R.H., Biedrzycki B., Laheru D., Schepers K., Sauter P.R., Goemann M., Coleman J., Grochow L., Donehower R.C., et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001, 19:145-156.